| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Peptide subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia, and Vaxxinity, Inc.[2] It is a peptide vaccine.[3][4]
It is composed of SARS-CoV-2 S1-RBD protein and synthetic peptides representing T cell (Th and CTL) epitopes on the nucleocapsid, spike and membrane proteins. The multitope composition is differentiated from other solely spike-protein based vaccines. By recognition against epitopes on Spike (S1-RBD and S2) and non-Spike (N and M) structure proteins, UB-612 provides B-cell and T-cell memory immunity and offers a potential as a universal vaccine to fend off the Omicron variant and new emerging variants of concern.[5][6] Vaxxinity began seeking regulatory approval for UB-612 for use as a booster vaccine in the United Kingdom and Australia in 2022.[7][8]
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ Liao G (27 June 2021). "Taiwan's second domestic COVID vaccine's midterm performance in phase II trials inferior to local competitor: experts". Taiwan News. Retrieved 8 July 2021.
- ^ Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L (12 July 2021). "SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants". Frontiers in Immunology. 12: 701501. doi:10.3389/fimmu.2021.701501. PMC 8311925. PMID 34322129.
- ^ "COVID-19 Vaccine". Vaxxinity. Archived from the original on 9 October 2021. Retrieved 9 October 2021.
- ^ Wang CY, Hwang KP, Kuo HK, Peng WJ, Shen YH, Kuo BS, et al. (May 2022). "A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants". The Journal of Clinical Investigation. 132 (10). doi:10.1172/JCI157707. PMC 9106357. PMID 35316221.
- ^ Guirakhoo F, Wang S, Wang CY, Kuo HK, Peng WJ, Liu H, et al. (October 2022). "High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster". The Journal of Infectious Diseases. 226 (8): 1401–1406. doi:10.1093/infdis/jiac241. PMC 9278180. PMID 35723969.
- ^ Lynch R (9 February 2023). "Vaxxinity moves HQ, jobs to Florida's Space Coast from Texas". Orlando Business Journal. American City Business Journals. Retrieved 26 February 2023.
- ^ Lorenz J (2 November 2022). "Phase 3 Trial of Vaxxinity's COVID-19 Vaccine as a Heterologous Booster Advances". ContagionLive. Retrieved 26 February 2023.